Fig. 3
Evaluation of safety and efficacy after repeated systemic administration of hDPSCs into CXMDJ. a Schematic representation of the hDPSC-treatment schedule in CXMDJ. b Early life growth and c serum chemistry data, such as alkaline phosphatase (ALP), aspartate aminotransferase (AST), and blood urea nitrogen (BUN) of normal dogs, untreated CXMDJ (control DMD; 12202MA, 13303MA, 14102MA), and hDPSC-treated CXMDJ (hDPSCs-DMD; 12205MA, 13201MA, 13304MA) after each administration throughout the experimental period. d Behavioral activity (day and night) in the home cage of normal dogs (13301MN, 14103MN) and CXMDJ (control DMD; 13303MA, 14102MA, and hDPSCs-DMD; 13201MA, 13304MA) at the age of 48–50 weeks, represented as mean activity counts (mean ± SD) observed every day and night. Statistical differences show normal vs. hDPSCs-DMD (*P < 0.05), and control DMD vs. hDPSCs-DMD (##P < 0.01), t test